INTASYL® siRNA gene silencing technologies that make immune cells more effective in killing cancer cells
Latest Presentations
Who we are
We’re a clinical stage biopharmaceutical company co-founded by a Nobel Prize scientist, Craig Mello, who discovered RNAi. Phio leveraged this legacy to advance siRNA therapies, which are derived from RNAi.
Our Science
Our proprietary INTASYL siRNA technology focuses on the application of self-delivery into the cells in the field of immuno-oncology.
Pipeline
Phio is focused on key initiatives for the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma.
Investors
Phio has brought on new leadership as it pivots from discovery to development.
